The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Uneasy alliance—clinical investigators and the pharmaceutical industry
Abstract
Clinical practice is changing rapidly. New cardiovascular drugs, antiinflammatory drugs, cancer chemotherapy, and other pharmacologic weapons are being added to physicians' therapeutic armamentarium virtually daily. Most clinical studies that bring new drugs from bench to bedside are financed by pharmaceutical companies. Many of these drug trials are rigorously designed, employing the skills of outstanding clinical researchers at leading academic institutions.But academic medical centers are no longer the sole citadels of clinical research. The past 10 years have seen the spectacular growth of a new research model. Commercially oriented networks of contract-research organizations (CROs) and site-management organizations (SMOs) have altered . . .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“COVID-19 case surges may cause disruption over a wide spectrum of societal and healthcare system activities. 1,385 387”
From European Resuscitation Council Guidelines 2021: Ethics of resuscitation and end of life decisions (2021) · cites this paper as [387]
Citations
Cites
Conflict of Interest in the Debate over Calcium-Channel Antagonists
Stelfox, H. T., Chua, G., O'Rourke, K., & Detsky, A. S. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380206 · Cited by 615
Source of funding and outcome of clinical trials
Davidson, R. A. (1986) · Journal of General Internal Medicine · doi:10.1007/bf02602327 · Cited by 397
Problems in the Design and Reporting of Trials of Antifungal Agents Encountered During Meta-analysis
Johansen, H. K. (1999) · JAMA · doi:10.1001/jama.282.18.1752 · Cited by 128
Research works printed but not linked: 29
- Cho MK, 1996, Ann Intern Med, 124, 485, 10.7326/0003-4819-124-5-199603010-00004 · DOI
- 10.1001/jama.282.15.1453 · DOI
- Chow S-C, Liu J-P. Design and analysis of clinical trials. New York: John Wiley, 1998.
- 10.1001/jama.282.8.786 · DOI
- 10.1001/jama.282.20.1947 · DOI
- 1997, CenterWatch, 4, 1, 9
- Henderson L, 1999, CenterWatch, 6, 1, 4
- Vogel JR, 1999, Appl Clin Trials, 8, 56
- 1997, CenterWatch, 4, 1
- 10.1017/S0266462300009582 · DOI
- Rochon PA, 1998, CMAJ, 159, 1373
- 10.1001/archinte.154.2.157 · DOI
- 10.1001/jama.282.8.790 · DOI
- 10.1001/jama.277.15.1224 · DOI
- 10.1001/jama.263.10.1405 · DOI
- 10.1056/NEJM199808133390701 · DOI
- Phillips RA, 1998, CMAJ, 159, 955
- 10.1001/jama.277.15.1238 · DOI
- 10.1001/jama.277.4.297a · DOI
- 10.1016/S0140-6736(05)75272-7 · DOI
- 10.1016/S0140-6736(05)80075-3 · DOI
- 10.1001/jama.271.6.469 · DOI
- 10.1056/NEJM199409083311012 · DOI
- 10.1001/jama.280.3.222 · DOI · Paper page
- 10.1001/jama.277.11.927 · DOI
- 10.1056/NEJM199812173392512 · DOI
- Kunin CM, 1978, Ann Intern Med, 89, 842, 10.7326/0003-4819-89-5-842 · DOI
- 10.1001/jama.278.3.245 · DOI
- 10.1056/NEJM200005183422009 · DOI
Cited by
Sorted by citations
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,232
Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review
Bekelman, J. E., Li, Y., & Gross, C. P. (2003) · JAMA · doi:10.1001/jama.289.4.454 · Cited by 1,816
“For-profit contract research organizations now consume more than 60% of clinical research funding from industry, leveraging their ability to complete trials more rapidly and less expensively than academic institutions.(8) In addition, management of financial interests at the institutional level is particularly challen…”
Assessing the Gold Standard — Lessons from the History of RCTs
Bothwell, L. E., Greene, J. A., Podolsky, S. H., & Jones, D. S. (2016) · New England Journal of Medicine · doi:10.1056/nejmms1604593 · Cited by 664
Conflict of Interest in Medical Research, Education, and Practice
Institute of Medicine (2009) · National Academies Press eBooks · doi:10.17226/12598 · Cited by 835
“Funding arrangements with contract research organizations have also raised concerns about inappropriate control by industry sponsors (Bodenheimer, 2000; Mirowski and Van Horn, 2005; Shuchman, 2007; Lenzer, 2008).”
BackgroundHeres, S., Davis, J. M., Maino, K., Jetzinger, E., Kissling, W., & Leucht, S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.185 · Cited by 451
“We focused on several factors that have been discussed as potential sources of bias, including features of study design, dose ranges, titration schedules, statistics, reporting ofresults, and wording of findings (4,7,8).”
Background
Metadata
- Authors
- Bodenheimer, T.
- Corresponding author
- Bodenheimer, Thomas
- ORCID
- Bodenheimer, Thomas
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2000-05-18
- Volume
- 342
- Issue
- 20
- Pages
- 1539-1544
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2337821671
- Cited by
- 765
- References
- 0
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 8 · 2022: 10 · 2021: 10 · 2020: 17 · 2019: 11 · 2018: 14 · 2017: 18 · 2016: 11 · 2015: 14 · 2014: 20 · 2013: 31 · 2012: 34
- FWCI
- 51.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Topics
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- clinical investigators, pharmaceutical industry, contract research organizations, academic medical centers, clinical trials, conflicts of interest, drug development
- MeSH terms
- Academic Medical Centers, Authorship, Clinical Trials as Topic, Drug Evaluation, Drug Industry, Interinstitutional Relations, Publishing, Research Support as Topic, Social Change, United States, United States Food and Drug Administration, Conflict of Interest, Drug Approval, Disclosure, Contracts, Biomedical Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
